The importance of adjuvant formulation in the development of a tuberculosis vaccine. - Wikidata - wikimedia - TriplyDB

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

http://www.wikidata.org/entity/Q35783475

about

Vaccine development for tuberculosis: current progress Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis Current advancements and potential strategies in the development of MERS-CoV vaccines Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells.Novel vaccination approaches to prevent tuberculosis in children Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tuberculosis infection.BCG vaccine mediated reduction in the MHC-II expression of macrophages and dendritic cells is reversed by activation of Toll-like receptors 7 and 9.The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.Vaccine against tuberculosis: what's new?Immunization with Heat Shock Protein A and γ-Glutamyl Transpeptidase Induces Reduction on the Helicobacter pylori Colonization in Mice.A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.Combination vaccines against diarrheal diseases.Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses Current status of new tuberculosis vaccine in children.Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.Surfactin inducing mitochondria-dependent ROS to activate MAPKs, NF-κB and inflammasomes in macrophages for adjuvant activity.Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.Toll-Like Receptor Ligand-Based Vaccine Adjuvants Require Intact MyD88 Signaling in Antigen-Presenting Cells for Germinal Center Formation and Antibody Production.Comparative analysis of Bacillus subtilis spores and monophosphoryl lipid A as adjuvants of protein-based mycobacterium tuberculosis-based vaccines: partial requirement for interleukin-17a for induction of protective immunity.Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.Pattern recognition receptors in innate immunity, host defense, and immunopathology.Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection.

P2860

Q26827737-058EA6CE-122F-4D58-88D6-24981BF83ADF Q26863391-7CFB2C48-AD8D-4F44-9F6E-6F64DBFA27B0 Q27012578-E41A12F0-EEEE-4305-B3A9-7504F084D19C Q27025822-81977C2E-0B30-414F-8D4E-F7780040DCFC Q31076192-1FE97F6A-7DB7-4733-8C10-D1405EA291B8 Q33614952-89093744-A899-4248-B4F7-548B1B3BDC0F Q33703027-832F522A-A090-4726-97AC-936A74E33F00 Q33801426-1FC5B57F-BF0F-433C-9004-F9156A8E9541 Q33827831-8B9280F9-5AB0-404D-9FC7-FDD919267893 Q33893983-4FE566C5-10C8-44DA-AD13-36408B1802A2 Q34260863-3064AD4F-C2D1-45D6-AA83-B94B4A90D536 Q34298351-71C784EA-870B-408E-B1CB-2D28FE7F514B Q35101472-C9C14D65-5105-4CEA-8BAF-786F8A98482C Q35671658-D249573B-0E83-44C1-842E-8934094DB2D2 Q35849628-AAC5A886-58C2-426D-934C-E449201E8C33 Q35896237-954D5D2D-CF0E-45D5-9863-851DC492E19F Q36086281-A9D62505-D24F-42CE-826A-169583DD55CF Q36362230-853138C0-8C88-47EC-8866-6EE024B44C6C Q36372507-FE4E6F0A-31C8-4D2B-B067-635CB2E0C095 Q36555077-F4F3A605-D0DA-4EEC-A085-AFDDCA9FD6CB Q36909492-CFEFC562-BACD-4C14-A023-EE791624E115 Q36972226-603C13CA-113E-4446-AB20-39864CBD39A8 Q37130796-503589EA-ADA2-4607-9BC1-C678E3B6750F Q37218080-77517580-8F46-4C3E-9FAF-1ADECCED0C91 Q37239554-4405E584-4B96-4D6C-A609-EDFEC9560855 Q37240218-CAA080BA-F12C-4108-BA74-D9A7F2239A5E Q37243896-A2022ACF-3F0F-42C0-B78B-3F8C580DAAE4 Q37301506-DD993AC6-A3D6-490C-968D-680F1A021573 Q37410524-4A3A0567-9A76-4187-AD2A-38DA2F876B4D Q37431320-27D30558-D5A1-428C-99AD-1071E5850561 Q37501222-668FD3C6-6BF2-407F-A8DC-49C76F7C55F3 Q37641676-FD121921-2ADE-4E87-8443-FA1AB590AFEE Q37665484-043CA5DD-0F38-421E-8B8E-2D9BD685CD57 Q37677962-704A45A0-B163-4D71-95A7-E923C061B02E Q37712810-84EB3E81-B388-46A8-A768-80A2197DA7BF Q38124061-3E47DE11-75E9-4E6A-8E52-0EDEE8C147B0 Q38124063-4A09AA74-9C7B-4CB0-814F-0DACC8ED1833 Q38167648-DD12B754-4009-459A-8B34-B06F86B41502 Q38209327-3BA43F32-AC35-4971-BCC3-C60C836F4289 Q40089069-5A3932F5-C23E-4B4C-B71F-3265F674395A

P2860

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

http://www.wikidata.org/entity/Q35783475

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@ast

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@en

type

label

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@ast

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@en

prefLabel

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@ast

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@en

P1433

Q35783475-EFE0B1D8-A5A6-498F-90D1-D3F4EC35501E

P1476

Q35783475-728D5F07-FAE8-4418-AFBF-68717DE2AAAE

P2093

Q35783475-2D5B7841-BC04-44D3-98A6-297C9A848AFD

Q35783475-727EC877-27B5-4545-8AF1-00E4607A1E96

Q35783475-74F8F34D-AC2B-4154-A7DF-B88D327EE178

Q35783475-97D6F9F7-1F91-4385-AA73-8D25D89899A4

Q35783475-E181BF2B-F8AB-41C8-A651-53A4A596EEB7

P2860

Q35783475-0587FF23-4F38-44CD-8054-9EB74C8D98BF

Q35783475-29CE18F2-7954-4779-B551-5BAD2137A063

Q35783475-3F44127B-0643-417E-96D6-C927B91B6AA2

Q35783475-41CF06E0-CFF5-440C-9947-7C197397ACD7

Q35783475-52BA5C38-E58C-49B8-BFD8-931C373EB716

Q35783475-56857AB0-1009-4CC1-8C29-1277FC883C60

Q35783475-5C6D8A09-D1C0-49EB-A71E-E054F3D476C8

Q35783475-68275AB4-16AA-41E0-9528-70A336595AA6

Q35783475-78F6A094-57C9-4B5A-B30A-06E11680704B

Q35783475-912A5B9C-B372-4049-9CCD-BF7240C1DB9C

P304

Q35783475-5F91762F-33BE-488A-A7B5-B517E4819E9C

P31

Q35783475-1D4C89E9-2100-425D-96F4-7316E07F0F04

P356

Q35783475-69F41883-0639-4D67-8D2B-A86DB4178AFC

P407

Q35783475-405ABB86-B841-42D3-ADDA-498F4AF8864A

P433

Q35783475-106FF3A4-9B2F-42BD-AEF9-7EA50C55E51A

P478

Q35783475-D0FE106F-067E-4D43-86A6-4341CACDE309

P50

Q35783475-F181A197-13D9-4023-A431-8218F1BBE93E

P577

Q35783475-492BF3AB-DFF3-4AE0-9915-EA3A80B19F48

P5875

Q35783475-A3A5ACFA-3606-43F3-92E0-5EC51099D3BE

P698

Q35783475-3652C918-A2FC-40B1-96E9-EA64D5489A88

P921

Q35783475-AFFB8774-6B64-4A5D-853B-780309A1E4C4

P932

Q35783475-5FFAB599-AEE1-45E4-AB0F-34E79FC03675

P356

JIMMUNOL.1102696

P1433

Journal of Immunology

P1476

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

@en

P2093

Lance K Ching

http://www.w3.org/2001/XMLSchema#string

Rhea N Coler

http://www.w3.org/2001/XMLSchema#string

Susan L Baldwin

http://www.w3.org/2001/XMLSchema#string

Sylvie Bertholet

http://www.w3.org/2001/XMLSchema#string

Valerie A Reese

http://www.w3.org/2001/XMLSchema#string

P2860

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

Evaluation of new vaccines for tuberculosis in the guinea pig model.

Emulsion-based adjuvants for influenza vaccines.

Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies.

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Immune responses to tuberculosis in developing countries: implications for new vaccines.

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis

P304

2189-2197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1102696

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221792586

http://www.w3.org/2001/XMLSchema#string

P698

22291184

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3288309

http://www.w3.org/2001/XMLSchema#string